GEROPHARM and OOO “R-Pharm” (member of R-Pharm Group of Companies) have announced a strategic partnership to localise the production of medicines for the treatment of socially significant diseases in Azerbaijan.

The agreement provides for the localisation of secondary packaging processes for three insulin products at R-Pharm’s facilities in Azerbaijan, along with the launch of their commercial distribution: RinGlar (insulin glargine), RinFast (insulin aspart), and RinFast Mix (biphasic insulin aspart).

To date, the first production campaign for the localised insulins has been completed and the products have entered the commercial market.

According to the State Statistics Committee, in 2023, the number of diabetes patients in Azerbaijan was over 320,000, of which 30,000 patients had insulin-dependent diabetes. The Russia-Azerbaijan partnership aims to improve diabetes patients’ access to efficacious medicinal products.

The localisation of foreign pharmaceuticals in Azerbaijan marks a significant step towards providing local patients with high-quality medicines meeting international standards.

“GEROPHARM is the largest full-cycle insulin manufacturer in the CIS, and we are committed to sharing our expertise with our partners. We hope that our joint efforts with R-PHARM will contribute to improving Azerbaijan’s national healthcare system and the quality of life of diabetes patients”, says GEROPHARM CEO Petr Rodionov.

The R-Pharm pharmaceutical facility in Baku is one of the most advanced plants in the CIS, comprising production, laboratory, and logistics units. The plant covers an area of 4.6 hectares, is equipped with state-of-the-art technology, and produces over 250 million units annually.